Jens Hillengass, MD
Medical Oncology · Buffalo, NYNPI 1447748058
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,618 of the $48,855 with a category attached, or 83.1%. It is spread thinly across 17 manufacturers, the largest accounting for just 19.6%.
Across 59 payments — averaging $828.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$10K
- Regeneron$9K
- E.r. Squibb & Sons, L.L.C.$5K
- Sanofi$5K
- Beigene, Ltd.$5K
- Amgen$5K
- plus $11K from 11 others
Across 115 payments — averaging $44,210 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3.8M
- Janssen Research & Development, LLC$347K
- Bristol Myers Squibb$335K
- Pfizer$185K
- GSK$149K
- E.r. Squibb & Sons, L.L.C.$130K
- plus $141K from 2 others
What the payments were for
- Consulting fees$40,61883%
- Speaking & faculty fees$1,4543%
- Grants$840%
- Travel & lodging$5,66212%
- Food & beverage$1,0382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 13 | $9,557 |
| Regeneron | 10 | $8,925 |
| E.r. Squibb & Sons, L.L.C. | 8 | $5,348 |
| Sanofi | 2 | $5,118 |
| Beigene, Ltd. | 2 | $4,658 |
| Amgen | 2 | $4,595 |
| GSK | 1 | $2,925 |
| Johnson & Johnson | 3 | $2,606 |
| Janssen Scientific Affairs, LLC | 1 | $1,768 |
| Siemens Medical Solutions USA, Inc. | 1 | $1,200 |
| The Binding Site Inc. | 1 | $1,000 |
| AstraZeneca | 3 | $431 |
| Taiho Oncology, Inc. | 4 | $259 |
| Bristol Myers Squibb | 4 | $207 |
| Alnylam Pharmaceuticals Inc. | 1 | $106 |
| Legend Biotech USA Inc. | 2 | $79 |
| Gilead | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,855 in reported general payments places this provider in the 75th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $6,985 |
| Acyclovir | 40 | $560 |
| Dexamethasone | 24 | $244 |
| Levofloxacin | 32 | $177 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Buffalo
- Ehsan MalekBuffalo$826K
- Marco DavilaBuffalo$437K
- Saby GeorgeBuffalo$234K
- Nikhil KhushalaniBuffalo$193K
- Francisco Hernandez IlizaliturriBuffalo$158K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.